Safety, efficacy and pharmacokinetics of recombinant factor IX FC fusion protein in children with haemophilia B (KIDS B-LONG)

被引：0
|
作者：
Fischer, K. [1 ]
Kulkarni, R. [2 ]
Nolan, B. [3 ]
Mahlangu, J. [4 ]
Rangarajan, S. [5 ]
Gambino, G. [6 ]
Diao, L. [6 ]
Cristiano, L. M. [6 ]
Pierce, G. F. [6 ]
Allen, G. [6 ]
机构：
[1] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
[2] Michigan State Univ, Lansing, MI USA
[3] Our Ladys Childrens Hosp, Dublin, Ireland
[4] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa
[5] Basingstoke & North Hampshire Hosp, Basingstoke, Hants, England
[6] Biogen Idec Inc, Cambridge, MA USA
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2015年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
LB009
引用
收藏
页码：87 / 87
页数：1
相关论文
共 50 条
  • [11] Subject-Reported Changes in Physical Activity During The B-LONG Study of Recombinant Factor IX FC Fusion Protein (RFIXFC) For Severe Haemophilia B
    Windyga, J.
    Ragni, M.
    Pasi, J.
    Shapiro, A. D.
    Ozelo, M.
    Innes, A.
    Mei, B.
    HAEMOPHILIA, 2015, 21 : 29 - 29
  • [12] Treatment of bleeding episodes in subjects with haemophilia B with the long-lasting recombinant factor IX Fc fusion protein (rFIXFc) in the phase 3 B-LONG study
    Pasi, J.
    Josephson, N.
    Mahlangu, J.
    Perry, D.
    Powell, J.
    Ragni, M.
    Valentino, L. A.
    Krassova, S.
    Nugent, K.
    Brennan, A.
    Innes, A.
    Luk, A.
    Pierce, G. F.
    Allen, G.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 359 - 359
  • [13] Recombinant factor IX Fc fusion protein as episodic treatment for bleeding: Analysis from the B-LONG Study
    Pasi, John
    Ragni, Margaret
    Ozelo, Margaret
    Valentino, Leonard A.
    Jiang, Haiyan
    Dodd, Nigel
    Robinson, Brian
    Mei, Baisong
    Pierce, Glenn
    HAEMOPHILIA, 2014, 20 : 15 - 16
  • [14] Clinical trial for long-lasting recombinant factor IX-FC (rFIXFc) in subjects with haemophilia B (B-LONG)
    Luk, A.
    Jiang, H.
    Gust, S.
    Defeo-Fraulini, T.
    Roberts, A.
    Pierce, G.
    HAEMOPHILIA, 2011, 17 (02) : 355 - 355
  • [15] Safety, efficacy, and improved pharmacokinetics (PK) demonstrated in a phase 3 clinical trial of extended half-life recombinant FC fusion factor IX (B-LONG)
    Powell, J.
    Ozelo, M.
    Pasi, J.
    Ragni, M.
    Valentino, L.
    Mahlangu, J.
    Josephson, N.
    Perry, D.
    Baker, R.
    Novitzky, N.
    Krassova, S.
    Allen, G.
    Campion, M.
    Jiang, H.
    Li, S.
    Goyal, J.
    Sommer, J.
    Dumont, J.
    Brennan, A.
    Vigliani, G.
    Luk, A.
    Pierce, G.
    HAEMOPHILIA, 2013, 19 : 76 - 77
  • [16] Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B
    Pasi, K. John
    Fischer, Kathelijn
    Ragni, Margaret
    Nolan, Beatrice
    Perry, David J.
    Kulkarni, Roshni
    Ozelo, Margareth
    Mahlangu, Johnny
    Shapiro, Amy D.
    Baker, Ross I.
    Bennett, Carolyn M.
    Barnes, Christopher
    Oldenburg, Johannes
    Matsushita, Tadashi
    Yuan, Huixing
    Ramirez-Santiago, Alejandra
    Pierce, Glenn F.
    Allen, Geoffrey
    Mei, Baisong
    THROMBOSIS AND HAEMOSTASIS, 2017, 117 (03) : 508 - 518
  • [17] Safety, Efficacy, and Pharmacokinetics of Recombinant Factor VIII FC Fusion Protein (RFVIIIFC) in Previously Treated Paediatric Subjects with Severe Haemophilia A (Kids A-LONG)
    Young, G.
    Mahlangu, J.
    Kulkarni, R.
    Nolan, B.
    Liesner, R.
    Pasi, J.
    Barnes, C.
    Neelakantan, S.
    Gambino, G.
    Cristiano, L. M.
    Pierce, G. F.
    Allen, G.
    HAEMOPHILIA, 2015, 21 : 32 - 32
  • [18] Recombinant factor IXFc fusion protein in severe haemophilia B: association between fix activity and bleeding in B-LONG
    Hermans, C.
    Shapiro, A.
    Potts, J.
    Li, S.
    Valentino, L. A.
    Diao, L.
    Robinson, B.
    Pierce, G. F.
    Mei, B.
    Jiang, H.
    HAEMOPHILIA, 2014, 20 : 83 - 83
  • [19] Pharmacokinetic parameters of recombinant factor IX Fc fusion protein are not influenced by factor IX antigen levels in subjects from the Phase 3 B-LONG trial
    Sidonio Jr, Robert F.
    Casiano, Sandra
    Falk, Aletta
    Altincatal, Arman
    Katragadda, Suresh
    Santagostino, Elena
    Windyga, Jerzy
    HAEMOPHILIA, 2023, 29 (01) : 404 - 407
  • [20] Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B
    Shapiro, Amy D.
    Kulkarni, Roshni
    Ragni, Margaret V.
    Chambost, Herve
    Mahlangu, Johnny
    Oldenburg, Johannes
    Nolan, Beatrice
    Ozelo, Margareth C.
    Foster, Meredith C.
    Willemze, Annemieke
    Barnowski, Christopher
    Jain, Nisha
    Winding, Bent
    Dumont, Jennifer
    Lethagen, Stefan
    Barnes, Chris
    Pasi, K. John
    BLOOD ADVANCES, 2023, 7 (13) : 3049 - 3057
12345